Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasm Metastasis 1Melanoma 1Head and Neck Neoplasms 1Glioma 1Carcinoma, Renal Cell 1Advanced Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × Platinum Compounds × Clear all
NCT04906993 2025-09-09

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
443 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡